Background. Although prognosis of Chronic Granulomatous Disease (CGD) has greatly improved, few studies have focused on its long-term outcome. We studied the clinical course and sequelae of CGD patients diagnosed before age 16, at various adult time points.
Chronic granulomatous disease (CGD) is a primary immunodeficiency (PID) that affects approximately 1/200 000 to 1/250 000 live births [1, 2] . It is caused by a mutation in 1 of the 5 subunits of the nicotinamide dinucleotide phosphate (NADPH) oxidase [3, 4] , which leads to a reduction in the microbicidal activity of phagocytic cells. Starting at an early age, CGD patients suffer from severe recurrent infections [1] , as well as inflammatory events [5] .
The prognosis of CGD has greatly improved since its first description as a "fatal granulomatosis in children" [6] due to earlier diagnosis [7] , better management of infectious [2, 8] and inflammatory complications [9] , recommendation for prophylactic antibacterial [10] and antifungal [11] therapies, and improvement of allogeneic hematopoietic stem-cell transplantation (HSCT) [12] . While the median life expectancy of CGD patients in the 1980s was 10 years [13] , it is now more than 30 years [14, 15] .
Our knowledge of the clinical course of CGD in patients during adulthood, being limited to isolated case reports [16] [17] [18] or M A J O R A R T I C L E small series [19] , was expanded by a recent study that showed the major impact of pulmonary manifestations and sequelae in adult CGD patients [20] . Other insights on possible specific clinical features of adult CGD patients may also be deduced from previous studies; these include weight and height [21] , liver [22] complications, and specific characteristics of infection such as preferential sites of infection [23] , individual susceptibility to certain pathogens [24] , and the growing emergence of new pathogens responsible for severe infections [25] [26] [27] . Prolonged survival due to better management of infections has moved granulomatous [28] and autoimmune [29] manifestations to the forefront. Other complications, such as voriconazole-induced lupus [30] and fluoride excess periostitis [31] due to prolonged prophylactic treatment, are also a concern in this population.
Our objective in this study was to determine the clinical course of CGD in adult patients compared to that during childhood major infections and inflammatory complications and to determine the sequelae present among CGD adults, as well as the possible emerging complications and the favorable role of HSCT.
METHODS

Patients
Patients were screened using the French National Reference Center for PID registry, located at Necker-Enfants Malades University Hospital, Paris (CEREDIH, www.ceredih.fr). As previously described [5, 7] , data were first entered into the European Society for Immunodeficiencies online database (http://esid.org/Working-Parties/Registry).
Inclusion criteria included the following: a diagnosis of CGD made before and a date of last news (whether alive, dead, or lost to follow-up) after age 16. Among CGD patients included in the CEREDIH database by the time of first data collection (1 June 2012), 80 patients who met these inclusion criteria with sufficient available data were included (Supplementary Materials).
Data Collection
All data collected from the medical charts and files from June 2012 to June 2013, in a predefined case-report form, were carefully reviewed. General information included date of birth, sex, family-related cases, consanguinity, transmission mode of CGD, genetic diagnosis, mode of revelation of CGD (infection, inflammation, or familial screening), dates of first symptoms and diagnosis, diagnostic technique and its result, antiinfectious prophylaxis used (type and date of initiation), HSCT, post-HSCT outcome, date of last news, living status, and cause of death.
Only infectious events that led to hospitalization (ie, the most severe and best documented) were considered. Information on each infection included date, sites involved, pathogen, classification according to the EORTC/MSG 2008 criteria [32] of invasive fungal infections, ongoing antiinfectious prophylaxis and/or immunosuppressive therapy, mode of revelation, admission to an intensive care unit or surgical treatment, and circumstance of acquisition (community or nosocomially acquired).
Concerning inflammatory and autoimmune events, all episodes were noted independently of hospital admission. When inflammatory manifestations persisted, an episode was defined by a recurrence or an increase in symptoms that required new or reinforced treatment. The data collected included site of inflammation, histological results, treatment required (systemic or local corticosteroids, immunosuppressants, surgery, or other), and its duration.
Patient outcome was evaluated at the following key ages: age 16, reflecting the consequences of the events that had occurred during childhood; age 20, evaluating the outcome after the transitional period to an adult medical department; and beyond age 30. Assessment at these ages included height and weight, number of infections and inflammatory episodes during each time period, and social characteristics (school level, professional status, marital status). Respiratory evaluation included presence of chronic dyspnea, results of respiratory functional tests, and thoracic images. Digestive evaluation included stenosis, chronic fistulae, chronic diarrhea, or signs of malabsorption. Liver evaluation included biological abnormalities and signs of portal hypertension. Other chronic complications such as cytopenia, chronic renal insufficiency, and cutaneous lesions were also noted.
Ethics board approval was obtained for research on patients cared for by the CEREDIH (CCTIRS 06.327; 7 September 2006).
Statistics
Continuous variables were presented with their median or mean and minimum/maximum values. Survival analyses were performed using the Kaplan-Meier nonparametric model to estimate time to events. The threshold for statistical significance was set to P < .05 in all analyses. Statistical analyses were performed using R software [33] .
RESULTS
Patients' General Characteristics
Of the 80 patients included in the study, 36 (47.4%) had a sibling diagnosed with CGD. Five cases (7.2%) of parental consanguinity were documented (3 cases of p47 and 2 of p67 mutations). Most patients were diagnosed during the 1980s (Table 1) .
All patients received an antiinfectious prophylaxis that, by the late 1980s, consisted of a combination of trimethoprim-sulfamethoxazole and itraconazole [34] . One patient received prophylactic gamma-interferon [35] , while 22 others (27.5%) received gamma-interferon as part of a curative add-on therapy of a serious fungal infection when antifungals were not effective enough. Seven patients (9%), whose characteristics are detailed in Table 1 , underwent HSCT because of severe infections (3 patients), inflammatory episodes (3 patients), or both (1 patient).
Deaths
Ten patients died at a median age of 24.3 years (18.2-45.4). Nine patients died of infections, including 3 from cerebral abscesses (1 due to Klebsiella pneumoniae and 2 due to Aspergillus spp.), 2 from pneumonia (K. pneumoniae and Streptococcus constellatus), 2 from disseminated noncerebral aspergillosis, 1 from Staphylococcus aureus hepatic abscess, and 1 from Burkholderia cepacia bacteremia. For the last patient, the cause of death remained undetermined. The overall survival curve is provided in the Supplementary Materials.
Infections
A total of 553 infectious events occurred during the cumulated follow-up of all 80 patients (2076 patient-years). Each patient experienced at least 1 major infection, which occurred before diagnosis of CGD in 70/80 (87.5%) patients. The median age at the first infection was 0.94 year [0-23.9]. The most common sites of infections are listed in Table 2 . The main pathogens involved in all 553 infections are listed in Table 3 . Aspergillus spp. and S. aureus were the most common pathogens. More than a third of infections (35.6%) remained undocumented.
Inflammatory Episodes
A total of 224 inflammatory episodes occurred in 71 patients (88.8%) during follow-up and are described in Table 4 . Treatment of inflammatory episodes varied individually and over time. The most frequent therapy was corticosteroids (55.4%). In total, two thirds of all patients received oral corticosteroids at least once during the course of their disease. Immunosuppressants, including tumor necrosis factor-alpha (TNF-α) blockers in 5/71 (7%) patients, were mainly used after age 16 (8/8 cases for thalidomide).
Autoimmune Manifestations
Fourteen patients (17.4%) developed autoimmune complications (30 events in total), the most frequent being discoid lupus erythematosus (8 patients, 10%). Other autoimmune manifestations included isolated cases of cold agglutinin disease, immunoglobulin-A vasculitis, nonvirologically documented acute demyelinating encephalitis, immune thrombocytopenia, and antiphospholipid syndrome. One patient developed systemic lupus erythematosus associated with antiphospholipid syndrome, dermatomyositis, and interstitial diffuse pneumonia responsible for chronic respiratory failure. He died at age 35 of aspiration pneumonia and invasive aspergillosis.
Comparison of Infectious and Inflammatory Events Before and After Age 16
The main characteristics of infections were comparable before and after age 16, as shown in Tables 2 and 3 . Pulmonary infections were more frequent after age 16 (38% of all infections vs 28% before age 16), while lymph node infections were less frequent after age 16 (18% vs 27%), most often because they did not lead to hospital admission in adults (and thus were not accounted for). Consequently, a slightly greater proportion of invasive fungal infections occurred after age 16 (23.4% vs 16.2%).
Inflammatory manifestations were similar before and after age 16, as shown in Table 4 . Cutaneous inflammatory manifestations were more frequent after age 16 (18.3% vs 9.2%), presenting as severe inflammatory acne. The main difference appeared in the management of these inflammatory episodes, which involved more immunosuppressants after age 16 (20.2% of episodes vs 5.8%), mainly because of changes in clinical practices rather than because of their increased severity. Number of patients with neoplasia, n (%) 1 (1.25; lymphoma
Number of deceased patients, n (%) 10 (12.5)
Results are expressed as median (range, minimum-maximum) for quantitative variables and in total number (%) for qualitative variables.
Abbreviation: HSCT, hematopoietic stem-cell transplantation.
The median age of the first inflammatory episode was greater than that of the first infectious event (11.3 years vs 0.94 years, respectively; Table 1 and Figure 1 ). After excluding the 7 patients who had undergone hematopoietic stem-cell transplantation, the median annual frequencies of infectious events before and after age 16 Figure 2A and 2B.
Disease Burden of CGD
The overall burden of CGD due to its numerous infectious and inflammatory complications at different adult ages is summarized in Table 5 . The consequence of these complications also included growth failure, with a median height and weight among boys at age 16 of 162 cm (137-180) and 54 kg (33; 95), respectively.
Patients who had received corticosteroids before age 16 had a significantly lower median height of 157.5 cm (137-172) at age 16 compared to those who had remained steroid free (165 cm [148-180]; P = .003). At age 20, median height and weight remained lower than those observed in the general French population (168 cm (138; 185) and 56 kg (35; 80.5), respectively).
Seven of 80 (8.7%) patients complained of chronic dyspnea at age 16 and 4/17 (23.5%) did so after age 30. On thoracic computed tomography (CT) scans, nodules and micronodules were the most frequent abnormalities observed, but lung fibrosis and emphysema were also seen in 8 patients at age 16 (of 45 patients having undergone thoracic CT scans). Five patients (6.25%) had undergone a pulmonary lobectomy by the age of 16 years and 4 more patients after the age of 16, mainly due to an uncontrolled invasive fungal infection.
Concerning the digestive tract, 8.8% of patients showed chronic complications at age 16 chronic diarrhea (9%), bowel stenosis (7%), or chronic fistulae (7%), which often required multiple surgical interventions.
Regarding education, 53% of patients at age 16 attended high school (level expected for this age group), while others were either Results are expressed in absolute numbers of events (and % of all events) or in absolute number of patients (and % of total number of patients).
held back in middle school (30%), had entered alternate vocational educational programs (21%), or had quit school (3.8%). Among patients older than 30 years, 69% were employed, 50% were in a long-term couple relationship, and 2 (11.7%) had children. Among the 65 patients for whom a nitro blue tetrazolium test result was available, comparisons were made between those displaying microbicidal residual activity (24 patients) and those not displaying activity (41 patients). The former were significantly taller (165.5 cm vs 159.7 cm; P = .024), heavier (59.9 kg vs 51.2 kg; P = .022), and had a higher body mass index (21.9 kg/ m 2 vs 19.2 kg/m 2 ; P = .011) at age 16. However, no significant differences at age 16 were seen in terms of dyspnea, respiratory function test anomalies, digestive or hepatic complications, or annual frequency of infections or inflammatory events (Supplementary Table 1) .
DISCUSSION
As CGD patients grow older, the complications that arise in adults and long-term sequelae become a major concern [20, 36, 37] . This study is the first nationwide extensive study to focus on the long-term outcome of a large CGD pediatric cohort reaching adulthood. Using the French national CEREDIH registry [7] , we were able to retrospectively include every patient who matched the inclusion criteria followed in France.
Our study shows features comparable to those previously described (ie, age at diagnosis, proportion of X-linked inheritance [1, 14] ), characteristics of infectious and inflammatory events (sites of infections [1, 14] , pathogens implied, and sites of inflammatory episodes [1, 14] ). However, some important differences did appear. First, the proportion of patients in our study with an infection in any given site was greater than in previous cohorts, possibly because our study evaluated adult patients with a longer follow-up and greater risk of exposure to various pathogens. Another difference was a slightly increased proportion of invasive fungal infections (mostly Aspergillus spp.), possibly due to our focus on more severe infections, thus underestimating numerous milder nonfungal infections. Finally, some pathogens typically encountered by patients with CGD, such as Burkholderia and Nocardia [1] , were seldom isolated in this study. These latter results are in agreement with those of a European cohort where both bacteria were found in less than 1% of infections [14] .
Our study shows that infections and inflammatory episodes had the same characteristics during childhood and adulthood in CGD patients, despite the fact that patients had not received any prophylaxis before the first infectious events that led to diagnosis of CGD during childhood. The main difference concerned the management of inflammatory episodes after age 16 because a greater proportion treated with immunosuppressants. This difference was not due to a greater severity or likelihood of relapse of adult inflammatory episodes but rather because of evolution in clinical practices. In fact, before the late 1990s, the main treatment for inflammatory episodes consisted of short courses of oral corticosteroids. Infliximab was used for the first time in 1996 and thalidomide in 2004 [9] . Before these dates, most of the patients in our study were not yet 16 years. As a consequence, since immunosuppressants were mostly prescribed after age 16, a greater proportion of infectious events occurred under immunosuppressant therapy during adulthood. However, the retrospective design of our study did not allow us to determine if immunosuppressant use increased the risk of severe infections, as has been suggested for TNF-α blockers [38] .
Our study also shows that the first infectious event occurs much earlier than the first inflammatory episode during the course of CGD (median ages of 0.94 vs 11.3 years, respectively). As a result, while less than a third of all infectious events in our study occurred after age 16 (31%), 46% of all inflammatory episodes occurred during that same period. Furthermore, the overall annual frequency of inflammatory episodes tended to slightly increase after age 16, while that of infectious events tended to decrease. Thus, although infection remains a major concern in adults since it is the first cause of death [37] , inflammatory events nevertheless seem to predominate during adulthood.
Regarding chronic complications and sequelae in our adult CGD patients, the first was growth failure, as a consequence Results are expressed in number of occurrences (and % of the total number of episodes during the concerned period) and number of patients (and % of the total number of patients) involved by at least 1 specific flare.
of both serious infections and inflammation and of repeated steroid treatment before age 16. Second, chronic respiratory complications were frequent, as recently reported by our group [20] , and primarily due to repeated lung infections but also, in some patients, due to severe pulmonary inflammation. Chronic dyspnea affected almost one fourth of patients at age 30 due to mild chronic restrictive respiratory failure. The absence of systematic lung function testing may have further underestimated the proportion of patients with restrictive syndrome. Chronic digestive complications (including bowel stenosis, chronic perianal fistula), though less frequent, may nevertheless have a substantial impact on quality of life. Thus, although digestive inflammation does not influence the overall survival of CGD patients [39] , active treatment of these frequent episodes [5] is crucial. Only a few patients presented with chronic cholestasis. These results contrast with earlier data that showed that noncirrhotic portal hypertension may be a major complication during CGD, leading to increased mortality [22] . Finally, the consequences of such chronic complications and repeated hospital admissions on education were serious, with only half of the patients being able to follow a standard educational path. However, this did not seem to have an impact on further social and occupational integration, since most patients by age 30 had a job and half were committed in a long-term relationship.
A formal quality-of-life study would be required to properly address these questions.
In conclusion, we show that the outcomes of CGD relating to infectious and inflammatory events in adulthood follow a pattern similar to that during childhood. We also show that the disease burden of CGD at an adult age, due to the accumulation of infectious and inflammatory events over time, appears to be quite heavy, not only on a functional level but also on an educational level. Proper surveillance and follow-up are required for adult CGD patients, especially during the crucial transitional period from pediatric to adult medical departments. Regular clinical, biological, radiological, and functional follow-up should be performed in order to detect torpid infections, effectively treat inflammatory episodes, and prevent and properly manage chronic complications. Recent studies have shown that HSCT might be a better option than conservative management of CGD, since it reduces the number of serious infections, surgeries, and hospital admissions in children [12] . New therapeutic protocols (reduced-intensity conditioning regimen [40] , gene therapy protocols) are currently in development to offer a curative strategy for both children and adult CGD patients. However, the fact that some patients have an uneventful course of their disease, both during childhood and adulthood, suggests that not all patients require a curative treatment. Considering that in our study the clinical course of patients often remained equivalent between childhood and adulthood, patients with the most severe and frequent infectious or inflammatory events during childhood might be the best candidates for HSCT, especially since the outcome of these patients in our study was quite satisfactory.
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